Merck (MRK) - Fundamental Analysis Report 2026 (Updated)
Dear Readers, Welcome to Deep Research Global.
Executive TL;DR
Merck (MRK) delivered Q1 2026 worldwide sales of $16.3 billion, up 5% nominally, with KEYTRUDA family sales hitting $8.0 billion (12% growth), even as the company absorbed a $9.0 billion R&D charge tied to the Cidara Therapeutics acquisition.
Management raised the lower end of 2026 full-year revenue guidance to a $65.8 to $67.0 billion range and narrowed non-GAAP EPS to $5.04 to $5.16, reflecting confidence in oncology, animal health, and new launches such as WINREVAIR.
The company has aggressively rebuilt its post-Keytruda growth platform through three transformative deals: Verona Pharma ($10 billion), Cidara Therapeutics ($9.2 billion), and Terns Pharmaceuticals ($6.7 billion), supporting management’s $70 billion+ aspiration by the mid-2030s.
Key 2028 patent expirations on KEYTRUDA remain the defining risk; however, the subcutaneous KEYTRUDA QLEX launch, an emerging cardio-pulmonary franchise (WINREVAIR, Ohtuvayre, enlicitide), and a deep oncology pipeline create a credible bridge for investors with multi-year horizons.
Recommended - Read Full Reports
Read All Reports
Table of Contents
Executive TL;DR
Introduction
Merck & Co., Inc. Company Profile: Key Facts
Merck Investment Thesis
The Core Bull Argument
The Patent Cliff Reality
The Bridge Narrative
Merck Business Model Overview
Pharmaceutical Segment Mechanics
Vaccines Sub-Franchise
Animal Health Segment Mechanics
Capital Allocation Framework
Merck Revenue Analysis
Top-Line Trajectory
KEYTRUDA Family Deep Dive
GARDASIL: The Cautionary Tale
WINREVAIR: The Rising Star
Other Notable Product Lines
Latest Quarterly Earnings, Guidance, Margins, EPS Trajectory
Q1 2026 Earnings Quality
Margin Profile
EPS Trajectory in Context
Cash Flow Mechanics
Balance Sheet Health
Cash and Debt Position
Working Capital and Capital Structure
Merck Segment-by-Segment Teardown
Pharmaceutical Segment in Detail
Vaccines Sub-Franchise Detail
Animal Health Segment Detail
Major Merck Competitors
Merck vs. Bristol-Myers Squibb
Merck vs. Pfizer
Merck vs. AstraZeneca
Merck vs. Roche
Merck Strategic Context
The 2028 Patent Cliff Strategy
The Business Development Engine
The Oncology Separation Decision
The U.S. Drug Pricing Adaptation
Merck Valuation Framework
Multiple-Based Analysis
Free Cash Flow Yield
Dividend Yield Anchor
Sum-of-the-Parts Considerations
Bull, Base, and Bear Case Scenario Analysis
Bull Case Scenario
Base Case Scenario
Bear Case Scenario
Key Risks for Merck
Catalysts to Watch
Near-Term (2026)
Medium-Term (2027-2028)
Long-Term (Post-2028)
My Final Thoughts
Latest Analyst Price Targets
Official Sources and Data
Disclaimer: This analysis is for informational & educational purposes only and should not be construed as investment advice. Investors should conduct their own due diligence before making investment decisions. Past performance does not guarantee future results.
Introduction
Few pharmaceutical names carry the weight of expectations that Merck & Co., Inc. (MRK) does as of mid-2026.
The company is simultaneously running the most successful oncology franchise in pharmaceutical history and racing against the clock on its 2028 patent cliff. That tension defines every meaningful debate around this stock.
In this report you will find a granular teardown of segment economics, a sober look at the Cidara, Verona, and Terns deals that just reshaped the balance sheet, and a forensic view of how WINREVAIR, Capvaxive, Enflonsia, KEYTRUDA QLEX, and the enlicitide PCSK9 program could plug the post-2028 revenue gap.
For investors trying to separate signal from noise on Merck in 2026, the central question is not whether the patent cliff is real, but whether the bridge being built is engineered well enough to carry the company across it.
Merck & Co., Inc. Company Profile: Key Facts
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, is a global biopharmaceutical company headquartered in Rahway, New Jersey.
The company traces its U.S. lineage to 1891 and has since evolved into a Top 5 global pharmaceutical company by revenue.
The business is organized into two reportable segments: Pharmaceutical (covering human health prescription drugs, biologic therapies, and vaccines) and Animal Health (covering veterinary pharmaceuticals, vaccines, and digital health products).
Company Snapshot (as of May 31, 2026)
--------------------------------------------------
Ticker: MRK (NYSE)
Headquarters: Rahway, New Jersey, USA
CEO: Robert M. Davis (Chairman, CEO, President)
Founded (U.S.): 1891
Employees: ~71,000 (per 2025 10-K)
Reporting Segments: Pharmaceutical, Animal Health
FY 2025 Revenue: $65.0 billion
FY 2025 R&D Spend: Substantial (record investment per 10-K)
Quarterly Dividend: $0.85 per share (declared May 26, 2026)
2026 Revenue Guide: $65.8B – $67.0B
Rob Davis serves as chairman, chief executive officer, and president, having taken the helm in 2021.
The Animal Health business, while a smaller share of revenue, has emerged as a structural growth contributor.
The portfolio spans companion animal therapeutics led by BRAVECTO, livestock vaccines, and digital monitoring products that anchor a unique competitive moat in veterinary care.
Merck Investment Thesis
The Core Bull Argument
The bull case for Merck in 2026 rests on three structural pillars.
First, the underlying oncology engine is still accelerating, with KEYTRUDA expanding into earlier-stage indications and adjacent settings such as perioperative therapy.
Second, management has executed a credible offset strategy through both internal launches (WINREVAIR, Capvaxive, Enflonsia) and an aggressive but disciplined business development program (Verona, Cidara, Terns).
Third, the cash generation profile remains exceptional, with a free cash flow margin around 18.7% and a non-GAAP gross margin of 81.5% in 2025, giving the company financial flexibility to keep building.
The Patent Cliff Reality
The bear case is equally well-documented. Keytruda’s primary U.S. compound patent expires in December 2028, with additional secondary patents extending into mid and late 2029. Given the drug represents roughly half of total revenue, the loss-of-exclusivity scenario is a defining variable for any long-term thesis.
The 2025-2026 sales trajectory for Gardasil compounds the concern. The vaccine fell 39% in 2025 due to weakened China demand, demonstrating how quickly even iconic Merck franchises can stall under regional or geopolitical pressure.
The Bridge Narrative
For Merck to defend its current cash flow profile through 2030 and beyond, the bridge of new products needs to grow into the low-double-digit billions in aggregate sales.
Management’s $70 billion+ annual opportunity thesis hinges on ten priority programs delivering peak sales across cardio-pulmonary, oncology, and infectious diseases.
Investment Thesis Quick View
--------------------------------------------------
Strengths:
- World-leading oncology franchise (KEYTRUDA)
- 81.5% non-GAAP gross margin
- Robust pipeline with 80+ programs
- Strong dividend record + buyback authorization
- Diversified across human + animal health
Concerns:
- 2028 KEYTRUDA patent cliff
- Gardasil China demand collapse
- Single-product concentration risk
- U.S. MFN drug pricing pressure
The structural question is whether revenue replacement happens fast enough.
Even moderate analyst models suggest a multi-year revenue trough is possible without successful pipeline conversion, regardless of how strong the underlying gross margin appears today.
Merck Business Model Overview
Pharmaceutical Segment Mechanics
The Pharmaceutical segment generated roughly $58.1 billion in 2025, representing approximately 89% of total company revenue. This segment is itself split between branded human health prescription medicines and vaccines.
The structural economics of branded biopharma rest on three factors: scientific discovery (largely owned in-house with selective licensing), patent-protected pricing windows, and global commercial reach. Merck’s pharmaceutical franchise is built around oncology, cardio-pulmonary, vaccines, and rare disease therapeutic categories.
Within oncology, KEYTRUDA is a checkpoint inhibitor that binds to the PD-1 receptor, releasing the brake on a patient’s immune system to attack cancer cells. It is now approved across more than 40 indications spanning lung, head-and-neck, urothelial, melanoma, gastric, cervical, and many other tumor types.
Vaccines Sub-Franchise
The Vaccines portfolio sits within the Pharmaceutical segment and contributes meaningfully through products such as GARDASIL 9 (HPV), Capvaxive (21-valent pneumococcal conjugate), Enflonsia (RSV monoclonal antibody for infants), VAXNEUVANCE (15-valent pneumococcal), PROQUAD, MMR II, and ROTATEQ.
Capvaxive launched in 2024 and showed $129 million in Q2 2025 sales, scaling steadily through 2025 driven by retail pharmacy demand. Enflonsia received U.S. FDA approval in June 2025 to prevent RSV lower respiratory tract disease in infants, expanding into the RSV market dominated previously by Sanofi-AstraZeneca’s Beyfortus.
The vaccine business is unusually exposed to one-time policy and stockpiling dynamics. Q1 2026 included a year-over-year vaccine sales comparison challenge because a U.S. government stockpile lowered the year-ago base in Q1 2025.
Animal Health Segment Mechanics
Animal Health generated $6.4 billion in 2025 and accelerated to $1.79 billion in Q1 2026, growing 13% nominally and 6% excluding currency. This segment serves both companion animals and livestock producers.
The BRAVECTO line of parasiticides crossed $1.1 billion in 2025. The veterinary pharma category is structurally less exposed to U.S. drug pricing reform than human medicines, providing a useful diversification mechanism.
Business Model Snapshot
--------------------------------------------------
Revenue Sources:
1. Product sales (>95% of total)
2. Royalties and alliance revenue
3. Collaboration milestone payments
Geographic Mix (FY 2025):
- U.S. revenue: ~50%
- International: ~50%
Key Therapeutic Areas:
- Oncology, Vaccines, Cardio-pulmonary,
Diabetes, Infectious Disease, Animal HealthCapital Allocation Framework
Management has outlined a clear capital allocation priority order: fund the R&D engine, invest in capacity expansion, return cash to shareholders via dividends, then pursue accretive business development.
In Q1 2026 alone, after-tax R&D was $3.1 billion, capex was $1.0 billion, dividends paid totaled $2.1 billion, and business development absorbed $9.1 billion.
That deployment pattern matters because it demonstrates that even with aggressive M&A activity, Merck is not starving its organic engine or its dividend.